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Abstract
Phosphorylation at murine Serine 18 (human Serine 15) is a critical regulatory process for the tumor suppressor function of
p53. p53Ser18 residue is a substrate for ataxia-telangiectasia mutated (ATM) and ATM-related (ATR) protein kinases. Studies
of mice with a germ-line mutation that replaces Ser18 with Ala (p53
S18A mice) have demonstrated that loss of
phosphorylation of p53Ser18 leads to the development of tumors, including lymphomas, fibrosarcomas, leukemia and
leiomyosarcomas. The predominant lymphoma is B-cell lymphoma, which is in contrast to the lymphomas observed in
Atm
2/2 animals. This observation and the fact that multiple kinases phosphorylate p53Ser18 suggest Atm-independent
tumor suppressive functions of p53Ser18. Therefore, in order to examine p53Ser18 function in relationship to ATM, we
analyzed the lifespan and tumorigenesis of mice with combined mutations in p53Ser18 and Atm. Surprisingly, we observed
no cooperation in survival and tumorigenesis in compound p53
S18A and Atm
2/2 animals. However, we observed embryonic
lethality in the compound mutant animals. In addition, the homozygous p53Ser18 mutant allele impacted the weight of
Atm
2/2 animals. These studies examine the genetic interaction of p53Ser18 and Atm in vivo. Furthermore, these studies
demonstrate a role of p53Ser18 in regulating embryonic survival and motor coordination.
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Introduction
Ataxia telangiectasia (A-T) is a recessive childhood disease with
no cure. Patients with ataxia telangiectasia exhibit pleiotropic
symptoms, including ataxia, telangiectasia, early aging, radiosensi-
tivity and susceptibility to cancer [1]. The predominant childhood
malignancy is lymphoid malignancies, such a B-cell non-Hodgkin
lymphoma and T-cell lymphoid tumors (T-cell lymphoma and T-
cell acute lymphoblastic leukemia) [2]. Mutations in ataxia-
telangiectasia mutated (ATM, the gene mutated in A-T) have also been
detected in sporadic lymphoid tumors, such as T-cell prolympho-
cytic leukemia [3,4,5], B-cell chronic lymphocytic leukemia [6,7,8]
and mantle cell lymphoma [9]. In addition, other tumors, including
brain tumors and certain carcinomas, are also seen in patients
with A-T [10]. Studies also indicate a role for malignancy in
heterozygous carriers. For example, women who are heterozygous
carriers for A-T are at an increased risk for breast cancer [11].
Atm-null mice have been generated and can phenocopy several
aspects of the A-T disease. The Atm-null animals develop tumors,
predominantly lymphomas [12,13,14,15]. The tumor cell type
that develops is mainly immature T-cell thymic lymphoblastic
lymphoma [13,15]. Atm-deficient animals have been shown to
exhibit gross motor skill impairment [15]. In addition, cells from
Atm-deficient mice can exhibit some of the neurodegeneration
observed in A-T [16,17]. Additional studies have demonstrated
that Atm-deficient animals undergo early aging when crossed into a
telomerase deficient background [15,18]. Recently, a knock-in
mouse has been generated corresponding to the common human
ATM
763del6 observed in A-T patients [19]. The ATM
763del6
mutation produces an almost full-length protein that lacks kinase
activity. These mice had a longer life-span than Atm-null mice as
well as a reduction in the number of lymphomas. This observation
points to the fact that the outcome of the disease depends on the
nature of the ATM mutation in the patients [1].
The tumor suppressor function of ATM has been linked to its
role in DNA repair and checkpoint function [20,21,22]. The
checkpoint response is coupled in part to the phosphorylation of
downstream effector molecules, such as the tumor suppressor p53
[23]. ATM activates p53 directly or indirectly through activation
of its downstream kinase chk2, leading to p53-dependent responses
such as transient T-cell cycle arrest, senescence or apoptosis.
p53 is a critical tumor suppressor mutated in over 50% of
human malignancies. Regulation of p53 can occur through
phosphorylation of the amino-terminal transactivation domain
[24]. An important site for regulation of p53 function is the Ser15
(murine Ser18) residue, a substrate for ATM and ATR (ATM-
related) protein kinases. Studies of mice with a germ-line mutation
that replaces Ser18 with Ala (p53
S18A mice) have demonstrated
that phosphorylation of p53Ser18 is required for normal DNA
damage-induced PUMA expression and apoptosis, but not for
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S18A mice
developed lymphomas mostly of B-cell origin, which is in contrast
to the T-cell lymphomas which develop in Atm-null mice. These
mice also developed several malignancies, including fibrosarcoma,
leukemia, leiomyosarcoma, and myxosarcoma, which are unusual
in p53-null and Atm-null mice.
Thus,thephosphorylationsite Ser18onp53contributes totumor
suppression and regulation of lifespan in vivo. The p53Ser18 moiety
can be phosphorylated by additional kinases other than ATM,
suggesting there may be ATM-independent roles for p53Ser18.
Further support for this hypothesis is that p53Ser18 deficient
animals (p53
S18A mice) develop mostly B-cell tumors [26], which are
not observed in Atm
2/2 mice. In addition, it has also been shown
that p53 can have a tumor suppressive role in Atm-deficiency [26].
In order to examine the function of p53Ser18 in the process of
tumor suppression independent of ATM, we generated and
characterized compound p53
S18A and Atm-deficient animals.
Surprisingly, the status of p53Ser18 did not alter the survival of
Atm-null or Atm
2/+ mice. The tumor onset or profile of Atm-null mice
was also not affected by p53Ser18 status. However, we observed
embryoniclethalityinthecompound mutant animals.Furthermore,
cell cycle was greatly affected in cells from these animals.
Interestingly, we observed a decrease in weight in compound
Atm
2/2; p53
S18A/S18A animals compared to Atm
2/2 mice. We
present here our findings of the contribution of p53Ser18 to ATM-
mediated tumor suppression. Furthermore, these studies confirm
the importance of p53Ser18 in regulating tumorigenesis in vivo.
Materials and Methods
Ethics statement
All mice were housed in a pathogen-free facility accredited by
the American Association for Laboratory Animal Care (AALAC).
Mice were under protocol number 1032. Mice were bred under
standard conditions with a 12-hour light/dark cycle, and were fed
ad libitum with standard chow (Iso-Pro3000, Prolab). The
Institutional Animal Care and Use Committee of the University
of Massachusetts approved all studies using animals.
Mouse strains and tumor analysis
The generation and genotyping of the p53
S18A mice [25], p53
2/2
mice [27], Atm
2/+ and Atm
2/2 mice [15] have been previously
described. Because Atm
2/2 mice are sterile, Atm
2/2; p53
S18A/+ mice
wereinterbred toobtainthegenotype Atm
2/2; p53
S18A/S18A. Similar
age-matched cohorts of Atm
2/+, Atm
2/2, Atm
2/2; p53
S18A/S18A,
Atm
2/2; p53
S18A/+, Atm
2/+; p53
S18A/S18A,a n dAtm
2/+; p53
S18A/+
mice were established. All mice were on a mixed 129SvEv/C57Bl6
background. Litters with greater than 5 animals were included in
the offspring analysis. The survival and tumor data in the control
(wild-type) mice has been published [26]. The mice in the survival
analysis were observed twice a week for any signs of tumors or
distress. Mice were sacrificed when a tumor was apparent or when
the mice became unhealthy (severe weight loss, severe dermatitis, or
pronounced lordosis). Some animals were included in the survival
but not the tumor analysis because of post-mortem autolysis. The
mice were examined by necropsy to detect tumors or other gross
pathology and tissues were fixed in 10% formalin. Fixed tumors or
organs were embedded in paraffin and sectioned. Sections were
mounted on slides and stained with hematoxylin and eosin. Slides
were examined by a board-certified veterinary pathologist.
Cell culture and proliferation assays
Murine embryonic fibroblasts (MEFs) were generated from day
13.5 embryos. Since Atm
2/2 mice are sterile the compound
mutant MEFs were obtained from an Atm
2/+; p53
S18A/S18A
intercross. The MEFs were maintained in Dulbeccos’ Modified
Eagles Medium (DMEM) supplemented with 10% fetal bovine
serum, 5 mM glutamine, and penicillin and streptomycin (Invitro-
gen). The MEFswerecultured at sub-confluence and werepassaged
no more than 4 times, unless otherwise indicated. Cellular
proliferation/survival analysis was performed as described [25]
with pass 2 MEFs. Briefly, 2610
4 MEFs were plated onto each well
of a 6-well plate, and each day after plating MEFs from three plates
of each genotype were fixed, stained with trypan blue and
absorbance was determined. MEFs from two different intercrosses
were used for the experiments. Experiments were performed in
triplicate for each line and are presented as mean values with
standard deviations.
Rota Rod Experiment
The rotarod apparatus (Stoelting) was used to measure motor
coordination and balance, as well as the ability of mice to improve
motor skill performance with training. During training, mice were
placed on a rotarod accelerating from 4–40 RPM over 5 minutes.
Each mouse received ten trials (one trial every five minutes) and
the latency to fall off the rotarod in each trial was measured. The
following day, mice received three test trials on the accelerating
rotarod with each trial separated by one minute.
Data Analysis
Survival of mice was determined by Kaplan Meier analysis
using JMP software (SAS, Cary, NC). Pair-wise comparison of the
Kaplan Meier analysis was done using the Log Rank test.
Statistical analysis on perinatal lethality was done comparing
expected # per genotype for each litter compared to actual # per
genotype for each litter using a student’s t-test. MEF analysis was
done using student’s t-test on triplicate readings per time point.
Average latencies to fall from the rotarod were compared using
One-way Analysis of Variance followed by Tukey post-hoc tests.
Statistical significance was set at P,0.05.
Results
Growth Properties of Atm
2/2; p53
S18A/S18A Cells and
Animals
Cells from Atm-deficient animals exhibit decreased growth
properties, characterized by decreased cell proliferation [12]. We
compared the growth properties of Atm
2/2, p53
S18A/S18A and
compound Atm
2/2; p53
S18A/S18A MEFs. Figure 1A demonstrates
the results from a representative experiment, and cell lines were
plated in triplicate. Atm
2/2 MEFs exhibited a decrease in trypan
blue staining, which is correlative of slower proliferation,
compared to wild-type cells, as previously reported [12,15].
p53
S18A/S18A MEFs also exhibited decreased growth compared to
wild-type cells as previously described [25]. Cell lines generated
from heterozygous mice (p53
S18A/+ and Atm
2/+) grew similar to
wildtype cells (data not shown). The p53
S18A/S18A cells exhibited
greater rate of growth than Atm
2/2 cells (Figure 1A). Important-
ly, the cells used were early pass MEFs which do not exhibit the
significant number of senescenT-cells observed in higher pass cells.
Interestingly, the compound MEFs exhibited a proliferation rate
that was slower than p53
S18A/S18A MEFs, but not as slow as Atm
2/2
MEFs (Figure 1A). This suggested there was no cooperation in
the cell growth defects observed in the compound MEFs as they
did not grow slower than single mutant (Atm
2/2) MEFs. However,
there was a decrease on the growth of p53
S18A/S18A MEFs with the
loss of Atm, suggesting an additional site of ATM regulation on the
p53
S18A protein.
Tumor Analysis of p53S18A; ATM Mutant Mice
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2/2 mice exhibit additional growth defects including
decreased body weight [13,14,15]. We observed a significant
reduction in weight in Atm
2/2 animals compared to wildtype
animals at 5–6 months of age (Figure 1B). There was a further
significant reduction in body weight of Atm
2/2; p53
S18A/S18A
animals compared to Atm
2/2 animals. Importantly, p53
S18A
homozygous or heterozygous mice had a body weight similar to
wildtype. Thus, the presence of the p53Ser18 mutation synergizes
with loss of Atm in providing a growth advantage.
Prenatal Lethality in Atm
2/2; p53
S18A/S18A Animals
It has been reported that loss of p53 in an Atm-deficient
background leads to embryonic lethality [28]. The frequency of
Atm
2/2 offspring from 13 Atm
2/+ intercrosses was not significantly
reduced (Table 1, Cross A), confirming that loss of Atm does not
lead to embryonic lethality. Importantly, we previously observed
no embryonic lethality due to the p53
S18A mutation [26]. To
determine whether p53Ser18 loss would lead to perinatal lethality
in an Atm-null background, Atm
2/+; p53
S18A/S18A mice were
intercrossed and genotype of the offspring was analyzed
(Table 1, Cross B). The number of Atm
2/2; p53
S18A/S18A offspring
was significantly reduced in 25 litters, from the expected 25% to
16.9%. Thus, 30 out of the predicted 45.75 Atm
2/2; p53
S18A/S18A
mice were born, indicating about 35% of Atm
2/2; p53
S18A/S18A
offspring die prenatally. This percent is less than the 60% of
Atm
2/2; p53
2/2 mice which have been reported to die prenatally
[28]. However, it has been reported up to 15% of p53
2/2 mice
exhibit embryonic lethality [29]. Thus, although there is a prenatal
lethality associated with p53
S18A, it is not as robust as that with loss
of p53.
Analysis of mouse survival
To examine the role of p53Ser18 in an ATM-independent
survival, we performed a survival analysis to examine the effects of
p53
S18A in the survival of Atm
2/2 and Atm
2/+ mice. The Atm
2/2
mice had a rapid demise compared to wildtype mice (Figure 2A,
B). Of note, we observed a median survival of the Atm
2/2 mice of
41 weeks, which has been reported for the mice in the same
genetic background and mouse facility conditions [30]. Surpris-
ingly, Kaplan Meier analysis indicated that the presence of the
homozygous p53
S18A mutation had no significant effect on the
survival of Atm
2/2 mice (Figure 2A). However there was a
reduction in the survival of Atm
2/2; p53
S18A/S18A mice compared
to p53
S18A/S18A mice [26]. The presence of a heterozygous p53
S18A
mutation also had no effect on the overall survival of Atm
2/2 mice,
although the median was delayed (but not significantly)
(Figure 2A). The lack of cooperation in tumorigenesis is in
contrast to that observed for p53
2/2 animals, which demonstrate
cooperation in survival and tumorigenesis with Atm
2/2 mice [28].
We observed a significant decrease in the overall survival of
Atm
2/+ mice compared to wildtype mice (Figure 2B). In addition,
there was a significant decrease in the median survival. The
wildtype median survival age was 98 weeks, whereas the Atm
2/+
median survival age was 81 weeks. The mutation of one or two
alleles of p53Ser18 had no significant effect on the overall survival
Figure 1. Analysis of growth and development in Atm
2/2;
p53
S18A/S18A animals. A. Atm
2/2; p53
S18A/S18A MEFs exhibit a decreased
proliferation. Growth comparison between wildtype, Atm
2/2 and
Atm
2/2; p53
S18A/S18A MEFs (S18A=p53
S18A, WT=wildtype). B Atm
2/2
mice exhibit reduced weight. Weight of animals compared at 5–6
months of wildtype (n=10); Atm
2/2 (n=5); Atm
2/2; p53
S18A/S18A (n=8);
Atm
2/+; p53
+/+ (n=12); Atm
2/+; p53
S18A/+ (n=10); Atm
+/+; p53
S1A8/+
(n=9); and Atm
+/+; p53
S18A/S18A (n=12). The data presented are the
mean 6 S.E.M. Statistically significant differences are indicated with an
asterisk (*, P,0.05). n=# of animals.
doi:10.1371/journal.pone.0024813.g001
Table 1. Genotype of Offspring from Intercrosses.
Cross A: Atm
2/+; p53
+/+6Atm
2/+; p53
+/+ Total n=202
Genotype: Atm
+/+; p53
+/+ Atm
2/+; p53
+/+ Atm
2/2; p53
+/+
Obtained 46 (22.8%) 116 (57.4%) 40 (19.8%)
Expected 50.5 (25%) 101 (50%) 50.5 (25%)
T-Test 0.43 0.08 0.12
Cross B: Atm
2/+; p53
S18A/S18A6Atm
2/+; p53
S18A/S18A Total n=183
Genotype: Atm
+/+; p53
S18A/S18A Atm
2/+; p53
S18A/S18A Atm
2/2; p53
S18A/S18A
Obtained 50 (27.32%) 103 (56.28%) 30 (16.39%)
Expected 45.75 (25%) 91.5 (50%) 45.75 (25%)
T-Test 0.58 0.34 0.007
doi:10.1371/journal.pone.0024813.t001
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2/+ mice (Figure 2B). The median survival age for Atm
2/+;
p53
S18A/S18A and Atm
2/+; p53
S18A/+ mice was 90 and 81 weeks
respectively. Interestingly, we previously observed the median
survival age for p53
S18A/+ mice was 94 weeks [26], thus, the loss of
one allele of Atm further decreased lifespan of p53
S18A/+ mice. This
suggested that the residual ATM in Atm
2/+; p53
S18A/+ mice could
be phosphorylating the remaining p53Ser18 moiety, which would
explain the increased viability of p53
S18A/+ animals compared to
p53
S18A/S18A animals [26].
Analysis of Spontaneous Tumorigenesis in Atm and
p53Ser18 Deficient Mice
We analyzed spontaneous tumor development in Atm
2/2 and
Atm
2/2; p53
S18A/S18A animals. The predominant tumor observed
Figure 2. Survival and tumorigenesis of compound Atm deficient and p53
S18A mice. (A–B) Kaplan-Meier distribution of overall survival of
(A) Atm
2/2; p53
+/+ (n=21); Atm
2/2; p53
S18A/+ (n=19); Atm
2/2; p53
S18A/S18A (n=22); Atm
+/+; p53
S18A/+ (n=31); and Atm
+/+; p53
S18A/S18A (n=42) mice. (B)
Atm
+/+; p53
+/+ (n=12), Atm
2/+; p53
+/+ (n=21), Atm
2/+; p53
S18A/+ (n=24), and Atm
2/+; p53
S18A/S18A (n=24) mice over the course of two years. Percent
survival is on the y-axis and age of death (in weeks) is on the x-axis. Death was by either presence of tumor, illness or case unknown. n=# of animals.
(C–E) Highly invasive lymphoma in an Atm
2/2; p53
S18A/S18A animal. C. A lymphoblastic lymphoma comprised of monomorphic cells showing
complete effacement of the thymus (206) D. Spread of lymphoma to the spleen with effacement of splenic architecture (46). E. Higher
magnification of the lymphoma in spleen showing malignant lymphocytes (206). (F–H) Tumors in Atm
2/+; p53
S18A/+ animals. F. Marginal
lymphoma in the spleen of one animal (406). G. Abdominal histiocytic sarcoma in one animal showing some spindle shaped cells and characteristic
macrophages/histiocyte cells (206). H. Histiocytic sarcoma from same animal invading the kidney (46). (I–K) Tumors in Atm
2/+; p53
S18A/S18A
animals. I. Lymphoma present in the thymus of one animal, visible as a diffuse sheet of lymphocytes (206). J. Hemangiosarcoma present in the
spleen of another animal (46). K. Higher magnification of hemangiosarcoma in spleen showing almost complete effacement of the spleen (206).
doi:10.1371/journal.pone.0024813.g002
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incidence of lymphomas was 75% in Atm
2/2 mice, 100% in
Atm
2/2; p53
S18A/S18A mice and 91% in Atm
2/2; p53
S18A/+ mice.
The age of onset was similar for all genotypes. Lymphoma was
detected in the thymus and the surrounding organs and tissues in
all genotypes, reflecting the aggressive nature of tumors found in
Atm
2/2 mice [15]. By routine histology, there was a similar
morphological appearance in tumors of the three genotypes. In
Atm
2/2 animals, the majority of thymic lymphomas had a
lymphoblastic appearance, which, along with the thymic involve-
ment, was consistent with T-cell origin. Organs that were affected
as well also exhibited a lymphoblastic morphology. In addition,
poorly differentiated lymphomas were also observed in some thymi
in Atm-null animals. In these animals the lymphomas in the
surrounding tissue also had a more poorly differentiated
appearance. The majority of lymphomas in the thymus in
Atm
2/2; p53
S18A/S18A mice were also lymphoblastic and any
invaded surrounding tissue also had a lymphoblastic profile.
Representative micrographs of a highly infiltrative lymphoma in
an Atm
2/2; p53
S18A/S18A animal are shown in Figure 2C–E.
Mice on the Atm
2/2 background developed few cancers other
than lymphoma (Table 2). One bronchoalviolar carcinoma was
detected in an Atm
2/2 animal, and this animal also had a
lymphoblastic lymphoma in the thymus. In addition, one
malignant histiocytoma was observed in an Atm
2/2; p53
S18A/+
animal.
We observed a shortened life-span of Atm
2/+ mice compared to
wildtype animals (Figure 2B). We determined if Atm
2/+ and
compound Atm
2/+; p53
S18A animals also developed spontaneous
tumors. We detected an increase of tumor incidence in Atm
2/+
animals compared to wildtype animals. Whereas 23% of Atm
2/+
animals developed tumors, only 8% of wildtype mice developed
malignant tumors [26]. The tumors detected in Atm
2/+ mice were
lymphomas and a hemangiosarcoma (Table 2). A follicular
lymphoma in one animal involved the spleen, liver and also
mandibular lymph node. A poorly differentiated lymphoma in
another animal involved the liver and the spleen. The observed
hemangiosarcoma involved the spleen of one animal and had
ruptured.
The Atm
2/+; p53
S18A/+ animals also developed tumors, with a
penetrance of 35%. One animal had a marginal zone lymphoma
in the spleen (Figure 2F). Another two animals had follicular cell
lymphomas. One animal had a hemangioma in the liver. In
addition, one animal had an abdominal mass that was a histiocytic
sarcoma (Figure 2G) that had spread to the kidney (Figure 2H).
The tumor penetrance for Atm
2/+; p53
S18A/S18A animals was
16%. Interestingly, very few lymphomas were observed in Atm
2/+;
p53
S18A/S18A mice. This observation was in contrast with what we
had observed in p53
S18A/S18A animals where 35.7% of animals had
tumors, and 81% of tumors were lymphomas [26]. There was one
incipient lymphoma present in the thymus of one Atm
2/+; p53
S18A/
S18A animal, visible as a diffuse sheet of neoplastic lymphocytes
(Figure 2I). In addition, other animals developed an adenoma,
a fibrosarcoma, and a hemangiosarcoma in the spleen. The
hemangiosarcoma almost completely effaced the spleen (Figure 2
J,K).
We previously observed tumor-free p53
S18A animals that
presented with cellular alterations at the time of death that were
consistent with accelerated lifespan [26]. We observed some of the
same alterations in cellular composition in the compound Atm
2/+;
p53
S18A animals [26]. In the Atm
2/+; p53
S18A/+ mice we observed
alterations in the kidney, such as increased inflammation, tubular
cysts, hematomas and fibrosis. The Atm
2/+ mice also presented
with multifocal inflammation in liver. The Atm
2/+; p53
S18A/S18A
mice had liver inflammation and degeneration. Kidneys also had
increased inflammation as well as glomeruloneropathy. Further
analysis of a larger cohort of animals will be required to determine
if the animals are presenting with accelerated aging, as we
observed in the p53
S18A animals [26].
Performance on the rota rod apparatus
ATM has been shown to contribute to motor coordination [15].
We therefore tested motor coordination in p53
S18A animals to
determine if Ser18 contributes to this function. The accelerating
rotarod assay was used to measure motor coordination in p53
S18A
mice. All data were collected on age- and gender-matched naı ¨ve
animals. Immediately prior to training, mice were weighed.
Female wildtype and p53
S18A mice did not significantly differ in
weight; whereas male p53
S18A mice were modestly but significantly
heavier than wildtype mice (Figure 3A, B). During the training
phase, mice were placed on the accelerating rotarod for ten
consecutive trials over the course of one hour and latency to fall off
of the rotarod was recorded. Latency to fall off of the rotarod in
Table 2. Tumorigenesis in Atm and p53Ser18 deficient animals.
Atm
2/2
p53
+/+
Atm
2/2
p53
S18A/+
Atm
2/2
p53
S18A/S18A
Atm
2/+
p53
+/+
Atm
2/+
p53
+/S18A
Atm
2/+
p53
S18A/S18A
Mice Analyzed 11 16 16 15 14 18
Mice with tumors 8 12 12 3 5 3
Total tumors 8 13 13 3 5 4
Tumor Classification
Lymphoma 6 12 12 2 3 1
Histiocytoma 0 1 0 0 0 0
Histiocytic sarcoma 0 0 0 0 1 0
Hemangiosarcoma 0 0 0 1 0 1
Hemangioma 0 0 0 0 1 0
Fibrosarcoma 0 0 0 0 0 1
Carcinoma 1 0 0 0 0 0
Adenoma 1 0 0 0 0 1
doi:10.1371/journal.pone.0024813.t002
Tumor Analysis of p53S18A; ATM Mutant Mice
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S18A mice increased with successive trials
and reached a plateau by the tenth trial (Figure 3C, D). Twenty-
four hours after training, mice were again placed on the
accelerating rotarod and their performance was measured.
Compared to wildtype female animals, female p53
S18A animals
exhibited an increased latency to fall off of the rotarod (Figure 3E,
F(1, 9)=31.6, p,0.001). Conversely, male p53
S18A mice exhibited a
significant decreased latency to fall off of the rotarod compared to
male wildtype mice (Figure 3F,F (1,9)=5.8, p,0.05).
Discussion
ATM has been shown to have a role in DNA repair, DNA-
damage induced checkpoints, and telomere maintenance. p53 is a
substrate of ATM that is intimately linked with its role in DNA
repair and checkpoint function. We previously generated mice
with a germ-line mutation that replaces Ser18 with Ala (p53
S18A
mice). Studies with these mice and the same mice generated by
another lab have demonstrated that phosphorylation of p53Ser18
is required for normal DNA damage-induced PUMA expression
and apoptosis, but not for DNA damage-induced cell cycle arrest
[25,26,31]. In addition, p53
S18A mice developed late-onset
lymphomas at 18 months of age [26]. Studies indicate an ATM-
independent tumor-suppression function of p53 [32]. Our
observation that p53
S18A mice develop predominantly B-cell
tumors whereas Atm
2/2 mice develop T-cell tumors lead us to
hypothesize that there is an ATM-independent growth suppressive
role for p53Ser18. We investigated the role of p53Ser18 in the
tumor suppressor function of ATM by generating and character-
izing compound mutant animals.
Cells generated from Atm
2/2 and Atm
2/2; p53
S18A/S18A animals
grew slower than wildtype cells. In addition, p53
S18A/S18A cells
grew significantly faster than Atm
2/2 cells. However, there was no
synergy in the Atm
2/2; p53
S18A/S18A cells compared to the single
mutanT-cells (Figure 1A). This result was surprising, as there are
additional kinases that can phosphorylate p53Ser18 in an Atm
2/2
background. If the decreased proliferation induced by loss of Ser18
is due to regulation by an ATM-independent pathway in MEFs,
one could observe that the compound MEFs would have a
combined reduced proliferation. We observed a decrease in the
proliferation of cells from Atm
2/2; p53
S18A/S18A mice compared to
cells from p53
S18A/S18A mice. One possibility is that alternative
ATM sites are phosphorylated in the p53
S18A protein that
contribute to cell proliferation. Alternatively, in the absence of
ATM, another kinase can compensate at a secondary site of
phosphorylation, but not as efficiently. In addition to growth
defects, Atm
2/2 mice exhibit somatic growth defects [15].
Interestingly, we observed a significant reduction in the weight
Figure 3. Performance on an accelerating rotarod. Performance of wildtype (WT) and p53
S18A/S18A animals on a rotarod apparatus. Data for
female mice is on the left and male mice on the right. A–B Weight of animals tested. Data are presented as mean 6 standard deviation. C–D Training
of animals on rotarod. 4–5 month old animals were trained for 10 trials separated by 5 min. on an accelerating rotarod (0–40 rpm). The latency to fall
was recorded (n=5–6 mice/genotype/gender). E–F Average of three experimental trials 24 hrs. after training. Data are presented as mean 6
standard deviation. * P,0.05, ** P,0.01. Data were analyzed by two-tailed student’s t-test (A, B) and One-Way ANOVA followed by Tukey post-hoc
(C–F).
doi:10.1371/journal.pone.0024813.g003
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2/2; p53
S18A/S18A mice compared to Atm
2/2 animals at 5–6
months (Figure 1B). This is in contrast to our observations that
older p53
S18A animals are obese [33]. In addition, we observed
embryonic lethality in Atm
2/2; p53
S18A/S18A animals (Table 1),
although not to the same extent seen in Atm
2/2; p53
2/2 mice.
Interestingly, the overall survival of Atm-null mice was not
affected by the presence of a heterozygous or homozygous p53
S18A
allele. Of note, the median death of the Atm
2/2 mice we observed
is longer than reported for some studies [13,14,15], but similar to
animals maintained in comparable housing conditions [30]. This
observation confirms that the conditions of the mouse facility and
food can greatly affect the survival of Atm-deficient mice.
There was no cooperation in tumorigenesis observed in the
compound genotypes compared to Atm
2/2 mice (Figure 2A, B).
The majority of the p53
S18A animals in the Atm
2/2 background
succumbed to tumors and the tumors the animals developed were
similar (Table 2). The main tumor developed was thymic
lymphoma, which was either lymphoblastic or poorly differenti-
ated in appearance (Figure 2). The observation of predominantly
lymphoblastic lymphomas in Atm
2/2; p53
S18A/S18A animals is in
contrast to the B-cell lymphomas (follicular and centroblastic)
observed in p53
S18A/S18A animals [26]. In addition, the thymus was
rarely involved in p53
S18A/S18A animals.
The lack of cooperation in tumorigenesis suggests the Atm
2/2;
p53
S18A/S18A mice are still able to undergo tumor suppression in B-
cells in young animals, which is where p53
S18A/S18A mice develop
tumors with a greater latency. It is interesting that the time frame
is longer for tumors to arise in p53
S18A/S18A mice than in Atm
2/2 or
Atm
2/2; p53
S18A/S18A mice, suggesting the mechanism is different.
Indeed, tumors in Atm
2/2 thymocytes arise from translocations
[1], whereas as we linked the tumor suppression by p53Ser18 in B-
cells to defective apoptosis [26]. We have also linked apoptosis
effects of p53Ser18 to prevention of tumorigenesis by the Myc
oncogene [34]. An alternative explanation for the lack of synergy
in Atm-null and p53
S18A mutant animals may be that the
phosphorylation of Ser18 may be redundant in certain cell types
and at certain stages, but that later it plays a more critical role.
The synergy observed in compound Atm-null and p53-null mice
may be due to the fact that there are additional functions of p53
which are lost in p53-null animals but still retained in p53
S18A cells.
Nonetheless, the rapid demise of the Atm
2/2; p53
S18A/S18A
compound animals and the similar tumor type suggests that the
loss of Atm is dominant over the mutation in p53Ser18.
It has been reported that Atm
2/+ mice do not develop
spontaneous tumors, whereas Atm
763del6 mice have increased
cancer risk [35]. In our study, we found that the Atm
2/+ mice
had a decreased lifespan (Figure 2B) and developed tumors
(Table 2). The tumor penetrance was 23% for Atm
2/+ mice and
8% for wild-type mice. Our observation for tumors in Atm
2/+ mice
is different than that reported, and may be due to a combination of
different genetic backgrounds and housing specifications. Different
observations have also been reported for studies with radiation-
induced tumorigenesis: whereas some studies have reported an
increased incidence in radiation-induced tumors in Atm
2/+ mice
[36,37,38], another study has shown no effect of Atm heterozy-
gosity on radiation-induced tumors [39]. Our observation is
consistent with reports of increased risk of cancer in A-T
heterozygous carriers [40].
In addition to a role in tumor suppression, ATM also has a role
in motor function. A characteristic of A-T is ataxia. Although
Atm
2/2 mice do not display overt ataxia, they display defects in
motor behavior [15]. In order to assess motor coordination in
p53
S18A mice, we examined the performance of the mice on an
accelerating rotarod. We used animals at 4–5 months of age
(Figure 3). All mice used in the study improved rotarod
performance over successive trials during the training phase of
the experiment as evidenced by an increase in the mean time spent
on the rotarod before falling. Thus, mutant and wildtype mice did
not significantly differ in motor learning skills (Figure 3C, D).
Interestingly, during the test trial, female p53
S18A mice showed a
significant improved performance on the rotarod (Figure 3E).
Conversely, male p53
S18A mice exhibited a significant decrease in
performance on the rotarod during training (Figure 3F). A
significant, but modest, increase was seen in the weight of the
p53
S18A males, potentially influencing rotarod performance. No
weight difference was observed that would affect the results for the
female mice. This gender difference suggested the tumor profile
could exhibit gender differences. However, we examined the
tumor onset and type for the various genotypes and found no
gender difference for Atm mice on a p53
S18A background.
Nevertheless, these observations are the first to indicate a gender
difference associated with p53 phosphorylation and motor
coordination.
In summary, these studies further confirm the essential role of
the ATM/p53 pathway in tumor suppression. While loss of
p53Ser18 had no increased effects in survival and tumor
distribution in Atm-null mice, there appears to be a function of
p53Ser18 in mediating some of the role of ATM in embryonic
survival.
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